Altre lingue Arcturus Therapeutics Holdings Inc.

Azioni

ARCT

US03969T1097

Tempo reale stimato Cboe BZX Altri mercati azionari 18:35:56 25/04/2024			Variaz. 5gg	Var. 1 gen.
26,16 ^USD	-3,06%		-0,27%	-16,75%

27/03	L'insider di Arcturus Therapeutics Holdings ha venduto azioni per un valore di 610.574 dollari, secondo un recente deposito SEC	MT
21/03	L'insider di Arcturus Therapeutics Holdings ha venduto azioni per un valore di 299.839 dollari, secondo un recente deposito SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	27/03
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	21/03
Arcturus Therapeutics : Positive Results of Phase III Study of Bivalent Version of Kostaive®, Self-Amplifying mRNA Vaccine Against COVID-19 (Ancestral Strain and Omicron BA.4/5), for Booster Vaccination Conducted in Japan - Form 8-K	19/03
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	07/03
Arcturus Therapeutics: Q4 Earnings Snapshot	07/03
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M	07/03
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/03
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress	07/03
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference	26/02
Arcturus Therapeutics Holdings Inc. Announces Executive Changes	23/02
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission, for ARCT-032, for the Treatment of Cystic Fibrosis	23/02
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis	22/02
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis	22/02
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024	20/02
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster	05/02
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster	05/02
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems	05/01
CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	22/12
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	21/12
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster	21/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Arcturus Therapeutics Holdings Inc.

Azioni

ARCT

US03969T1097

Altre lingue

Filtri